Generated September 19, 2026.
Overview
CHPS and SMH are both semiconductor-focused equity ETFs, but they differ fundamentally in scale, approach, and maturity. SMH is a long-established index tracker backed by $66.8B in assets, while CHPS is a newer active or semi-active fund launched in 2023 with $113M under management. Both capture semiconductor sector exposure, but with different cost structures and trading profiles.
How they differ
The most obvious distinction: SMH is an index fund tracking the MVIS US Listed Semiconductor 25 Index, while CHPS does not disclose an index methodology, suggesting a non-indexed approach. That structural difference shapes everything downstream. Volatility is measurably different — SMH has a beta of 2.06, while CHPS shows 2.46, meaning CHPS is expected to swing harder with market moves. Finally, CHPS is barely a year old as of 07/12/2023, while SMH has operated since 12/20/2011, giving it a much longer track record.
- CHPS: Designed for investors willing to accept a newer fund's limited track record in exchange for a lower expense ratio and potentially more active or concentrated positioning within the semiconductor space.
Key risks to know
- Sector concentration: Both funds concentrate entirely in semiconductors; a sharp downturn in chip design, manufacturing, or demand affects both equally. Verify holdings overlap if considering them together.
- Higher volatility in CHPS: With a beta of 2.46 versus SMH's 2.06, CHPS amplifies semiconductor sector swings more dramatically, creating larger drawdowns in downturns and sharper recoveries in rallies.
- Fund age and track record: CHPS launched in mid-2023 and has not weathered a full market cycle; its non-indexed strategy and actual performance under stress remain unproven. SMH's longer history provides a clearer picture of behavior across different rate environments. Smaller ETFs can experience wider bid-ask gaps and higher slippage on large orders.
- Fee drag at different scales: Although CHPS charges 0.15% versus SMH's 0.35%, CHPS's lower fee advantage shrinks or vanishes if its strategy underperforms an index baseline or if smaller AUM limits operational efficiency. If you're drawn to a lower expense ratio and prefer an active or differently-weighted approach, CHPS presents an option—but you're accepting a fund with minimal operational history and significantly higher expected volatility. Neither choice is inherently superior; the trade-off hinges on whether you value the safety of an established index product or the cost efficiency of a newer, more concentrated strategy.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.